Magnesium Malate
SupplementThe divergence of -26 points arises because users report subjective improvements in energy and pain [c1, c2], while the clinical evidence specifically for magnesium malate is very limited — the only placebo-controlled RCT in fibromyalgia found no significant benefit [s1, s5].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Magnesium malate pairs magnesium's established role in ATP metabolism with malic acid as a Krebs cycle substrate — mechanistically sound, but clinically thin. The one positive fibromyalgia RCT (n=15) was not replicated by a subsequent placebo-controlled trial. Community consensus: energizing during the day, poorly suited for evening use — unlike glycinate. Safe, affordable, and well-tolerated; those taking magnesium primarily for sleep should choose glycinate instead.
Description
Magnesium malate combines magnesium with malic acid (malate) and is used for energy metabolism, muscle recovery, and fibromyalgia symptoms [s1, s2].
Magnesium malate is an organic magnesium compound in which the mineral ion magnesium is bound to malate (salt of malic acid). Malic acid is a natural constituent of fruit and an important intermediate of the citric acid cycle (Krebs cycle), which is central to cellular ATP production [s2, s4]. Compared to inorganic magnesium forms (e.g., magnesium oxide with approx. 4% bioavailability), organic compounds such as malate, citrate, and glycinate show bioavailabilities between 40% and 66% in human studies [s3]. The bioavailability of magnesium malate is considered comparable to that of magnesium citrate [s3]. A 2018 rat study demonstrated higher bioavailability of malate versus citrate; however, transferability to humans has not been established [s11]. The best-known application is fibromyalgia: in an open-label pilot study (Abraham & Flechas, 1992), daily intake of 300–600 mg elemental magnesium combined with 1200–2400 mg malate over 8 weeks led to significant improvements in the Tender Point Index and myalgia symptoms [s1]. A subsequent placebo-controlled RCT (Russell et al.) found no significant difference versus placebo for fibromyalgia pain after a brief washout period, which limits the evidence for this indication [s1, s5]. As a daily dose, the BfR recommends a maximum of 250 mg elemental magnesium from dietary supplements, divided into at least two intakes per day [s8]. The EFSA also sets the Tolerable Upper Intake Level (UL) for supplemental magnesium at 250 mg/day [s9].
Legal Status (DE)
In Germany and the EU, magnesium malate is approved as an over-the-counter dietary supplement. Magnesium dl-malate is authorized by the EFSA as a permitted magnesium source for dietary supplements [s9, s10].
Mechanism of Action
Magnesium malate acts via two complementary components: 1. Magnesium mechanism: Magnesium is a cofactor for over 300 enzymes and is essential for ATP synthase as well as all ATP-dependent reactions, since biologically active ATP exists as the Mg-ATP complex [s4]. Magnesium voltage-dependently blocks NMDA receptors and modulates neuromuscular transmission by inhibiting acetylcholine release at the motor endplate. Magnesium deficiency increases the release of substance P, a neuropeptide involved in pain perception, which may explain the association with fibromyalgia symptoms [s5]. 2. Malate mechanism: Malate (malic acid anion) is a direct intermediate of the citric acid cycle. It acts as an electron donor and enables maintenance of ATP production under anaerobic conditions — such as during muscle exhaustion — by feeding into the Krebs cycle [s2, s4]. This mechanism is the theoretical basis for the potential benefit in chronic fatigue and physical exertion [s2]. The combination of magnesium and malate is proposed to synergistically promote mitochondrial energy production while simultaneously reducing musculoskeletal pain through normalization of magnesium levels [s1, s5].
Dosing
Fibromyalgie und chronische Erschöpfung
- Dose
- 300–600 mg elemental magnesium (as malate compound)
- Frequency
- 2–3× täglich zu den Mahlzeiten
- Route
- oral
- Duration
- 8–24 Wochen
- Timing
- With meals for better tolerability
- With food
- empfohlen
Allgemeine Magnesiumversorgung und Energiestoffwechsel
- Dose
- 200–250 mg elemental magnesium
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Morning or with meals; not in the evening due to activating effect
- With food
- empfohlen
The BfR and EFSA recommend a maximum of 250 mg elemental magnesium from dietary supplements per day, distributed across at least two intakes [s8, s9]. Note: Doses exceeding 5,000 mg/day have been associated with magnesium toxicity [s6].
With magnesium malate products, attention should be paid to the elemental magnesium content — this is considerably lower than the total weight of the compound. The EFSA has evaluated magnesium dl-malate trihydrate as an approved source for dietary supplements [s9].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Durchfall, Magenkrämpfe) Typical side effect at higher magnesium doses; less pronounced with malate than with citrate or oxide, but possible [s6, s7]. | gelegentlich | leicht |
| Weicher Stuhl / leicht abführende Wirkung Magnesium malate can have a mild laxative effect at higher doses [s7]. | gelegentlich | leicht |
| Hypermagnesiämie (bei Überdosierung oder Niereninsuffizienz) Very high doses (above 5,000 mg/day) or severely impaired renal function can lead to hypermagnesemia with hypotension, respiratory disturbances, cardiac arrhythmias, and cardiac arrest [s6]. | selten | schwer |
| Aktivierende Wirkung / Schlafstörungen bei abendlicher Einnahme Users report that malate, unlike glycinate, tends to have a stimulating effect; evening intake may impair sleep onset [c1, c3]. | gelegentlich | leicht |
Contraindications
Impaired renal magnesium excretion leads to accumulation risk and hypermagnesemia with potentially life-threatening complications [s6, s8].
Elevated magnesium levels may further inhibit cardiac conduction [s6].
Magnesium inhibits acetylcholine release at the neuromuscular junction and may worsen muscle weakness [s6].
Chelation significantly reduces antibiotic absorption; a minimum interval of 2 hours is required [s8].
Interactions
Synergistic
Theoretically synergistic mitochondrial support: malate as a Krebs cycle intermediate and CoQ10 as an electron carrier in the respiratory chain. Clinical data are lacking [s2].
B vitamins are cofactors in energy metabolism and support the function of magnesium as an enzyme cofactor [s4].
Calcium and magnesium malate jointly support bone and muscle health. At high calcium doses (≥500 mg), simultaneous intake may reduce magnesium absorption; a 2-hour interval is therefore recommended.
Magnesium malate and potassium act synergistically in electrolyte balance and together stabilize the electrical activity of cardiac cells. Adequate supply of both minerals is particularly important for cardiac rhythm and athletic performance.
The combination of magnesium, vitamin D3, and K2 is considered the optimal trio for bone and muscle health as well as immune function. Magnesium is an essential cofactor for the activation of vitamin D.
The combination of ashwagandha and magnesium malate may reduce stress, improve sleep quality, and alleviate mental and physical fatigue. Several studies suggest synergistic effects on cortisol and the nervous system.
Magnesium malate and alpha-lipoic acid jointly support mitochondrial energy production. Malate as a Krebs cycle intermediate and alpha-lipoic acid as a cofactor of oxidative decarboxylation complement each other in energy metabolism.
Caution
Magnesium ions form chelate complexes with these antibiotics, reducing their bioavailability. Maintain a minimum interval of 2 hours [s8].
Magnesium can reduce the absorption of bisphosphonates; staggered administration is recommended [s6].
Additive hypotensive and cardiodepressant effects possible at elevated magnesium levels [s6].
At very high zinc doses (from approx. 142 mg/day), magnesium absorption may be impaired due to competition for shared transport proteins. At standard dosages (15–30 mg zinc), the interaction is not clinically relevant.
Studies
Tier A — High Evidence
Outcome: Summary of evidence for magnesium in fibromyalgia; malate-specific studies methodologically weak
Effect Size: Heterogeneous results; no clear effect size for magnesium malate specifically
Outcome: Improvement in tender point index and myalgia symptoms in fibromyalgia; Russell et al. no significant difference vs. placebo after short washout
Effect Size: Abraham: significant improvement (no exact effect size reported); Russell: no significant difference (p > 0.05)
Tier B — Moderate Evidence
Outcome: Approval of magnesium dl-malate and magnesium malate as sources for food supplements in the EU; UL 250 mg/day
Outcome: Bioavailability of organic magnesium compounds 40–66% vs. approximately 4% for magnesium oxide
Effect Size: Malate comparable to citrate; superior to oxide
Tier C — Low Evidence
Outcome: Role of malate as an intermediate of the citric acid cycle and magnesium as an ATP complex cofactor
Community Evidence
Top reported benefits
- Improved daytime energy and reduced fatigue
- Reduced muscle pain and cramps
- Good gastric tolerability
- Improvements in fibromyalgia symptoms
- Improved physical performance
Top reported issues
- Activating effect – less suitable for evening administration
- No noticeable effect in some users
- Mild laxative effect at higher doses
Users clearly distinguish malate from glycinate: malate is classified as energy-promoting (morning use), glycinate as calming (evening use). Few users test malate in isolation — frequent combination with other supplements complicates assessment of its individual effect [c1, c2, c3].
Scientific Sources
- Magnesium and Fibromyalgia: A Literature Review
Boulis M, Boulis M, Clauw D (2021). Journal of Primary Care & Community HealthBPMID:34387140DOI - Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2018). EFSA JournalADOI - Magnesium-Malat hochdosiert
Verbraucherzentrale Deutschland (2023). Verbraucherzentrale.deBLink - Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study
Russell IJ, Michalek JE, Flechas JD, Abraham GE (1995). Journal of RheumatologyCPMID:8587088 - Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best?
Uysal N, Kizildag S, Yuce Z, et al. (2018). Biological Trace Element ResearchCDOI - Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements
Turck D, Castenmiller J, De Henauw S, et al. (EFSA NDA Panel) (2018). EFSA JournalCDOI - Chronic Organic Magnesium Supplementation Enhances Tissue-Specific Bioavailability and Functional Capacity in Rats: A Focus on Brain, Muscle, and Vascular Health
Uysal N, et al. (2025). Biological Trace Element ResearchCDOI - Magnesium Malate for Energy: Benefits, Dosage and Athletic Performance
MitoHealth Editorial (2024). MitoHealth.com (narrative review)CLink - Magnesiumformen im Vergleich: Bisglycinat, Citrat, Malat & Oxid
Ayuba Nutrition Editorial (2023). Ayuba Nutrition Blog (Übersicht Humanstudien)CLink - Review on Effects of Magnesium in Energy Metabolism and Exercise
JETIR Review Authors (2024). Journal of Emerging Technologies and Innovative Research (JETIR)CLink - Magnesium for Fibromyalgia: Types, Benefits, Dosage & More
Human Health Editorial (2024). Human.health (Übersicht klinischer Studien)CLink - Magnesium – Health Professional Fact Sheet
National Institutes of Health (NIH), Office of Dietary Supplements (2024). NIH Office of Dietary SupplementsALink - Magnesium: Benefits, Best Forms, Dosing, and Side Effects
Stanfield B (2024). DrStanfield.com (narrative review)CLink - Höchstmengenvorschläge für Magnesium in Lebensmitteln inklusive Nahrungsergänzungsmitteln
Bundesinstitut für Risikobewertung (BfR) (2021). BfR – Bundesinstitut für RisikobewertungALink - Evaluation of di-magnesium malate, used as a novel food ingredient and as a source of magnesium in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2020). EFSA JournalADOI
Community Sources
Storage
Unopened
Store in a dry place at room temperature; protect from direct sunlight and moisture.
Opened
Seal packaging tightly after use; protect powder forms especially from moisture absorption.
Notes
No refrigeration required. Quality degradation through moisture absorption is possible (clumping in powder form).